肺癌脑转准备尝试拉帕替尼特别请jimmy进来看看

amei

谢谢，具体应该怎么服用呢？是否按照乳腺癌的剂量服用呢？发生间质性肺炎的几率有多少呢？

救父涂存

amei,特罗凯也耐药了吗？？真为你担心。

我的同事告诉我，他联系过你了，他说你很专业，很热心，谢谢你。

希望你一切顺利，你这样细致这样有心，上天一定会眷顾你的。再次祝福。。。

amei

图存：

    你客气了，我只是一个门外汉，所作的治疗也并不是干细胞移植，所以给出的意见肯定不够专业，如果能帮到你的同事我也很高兴，真是同是天涯沦落人。最近2个月一直奔走于医院和单位，没有多少时间上网聊天了，看到你父亲服用易瑞沙一直稳定，默默祝福你。

jimmy112199

QUOTE:

以下是引用amei在2008-5-9 12:34:44的发言：
谢谢，具体应该怎么服用呢？是否按照乳腺癌的剂量服用呢？发生间质性肺炎的几率有多少呢？

上文所述5例稳定，药量为500-1600MH/日，下文中为一组1500MG/日，另一组500MG，每日俩次，疗效无差别。都不太好

A phase II multicenter trial comparing two schedules of lapatinib (LAP)
as first or second line monotherapy in subjects with advanced or
metastatic non-small cell lung cancer (NSCLC) with either
bronchioloalveolar carcinoma (BAC) or no smoking history.

Abstract No:	7611
Citation:	Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 7611
Author(s):	M. Smylie, G. R. Blumenschein, A. Dowlati, J. Garst, F. A. Shepherd, J. R. Rigas, H. Hassani, M. S. Berger, T. Zaks, H. J. Ross
Abstract:	Background: LAP (GW572016) is an oral reversible, dual tyrosine kinase inhibitor of EGFR (ERBB1) and HER2/neu (ERBB2). This study was designed to test the activity of 2 dose schedules of LAP in chemotherapy naïve pts with NSCLC; it was amended to target patients with either BAC or no smoking history in the first or second line and to evaluate the relationship of mutations in target genes to responses. Methods: LAP was given orally 1,500 mg once (QD) or 500 mg twice daily (BID) until progression or intolerance. Safety and efficacy (RECIST) were assessed every 4 & 8 weeks. The primary endpoint was response. The target (BAC/no smoking) and non- target populations were assessed for efficacy, and tumor tissue was analyzed for ERBB1 and ERBB2 mutations and/or amplifications. Results: The study was stopped for futility after 131 pts were randomized (65 QD, 66 BID). Median age 66 (range 32-86); female 56%; BAC 20%, No BAC 71%; previously untreated 98.5%; current/former smokers 70%, never smoker 30%. There were no complete responses. Of 56 pts in the target population, 1 (2%) achieved partial response (PR), 11 (20%) had stable disease (SD) of >24 wks; in the non-target population, 1 pt had a PR (1.3%) and 12 (16%) had SD of >24 wks. 3 pts had ERBB1 mutations (G719S, S768I, KRAS G12S; L858R and T790M; L858R) but none of them responded. There were no ERBB2 mutations. Three of 77 pts evaluated had ERBB1 gene copy increase (none of whom responded) and 2 had ERBB2 gene copy increase (one had a 51% decrease in tumor size). The most common adverse events were grade 1/2 diarrhea, nausea, rash, vomiting and fatigue, and were similar in both groups. Conclusions: LAP was well-tolerated, with no notable difference in toxicity between the QD and BID groups. Very few responses were seen, stable disease was sometimes prolonged. The prevalence of mutations was low even in the target population. Given the preclinical synergy between LAP and other agents, further studies will be necessary to determine whether LAP is active in combination with other agents for the treatment of NSCLC.

[此贴子已经被作者于2008-5-10 9:36:08编辑过]

amei

谢谢JIMMY，看了你给的资料，实在不知如何是好，因为我妈妈全放无效，易瑞沙，特罗凯耐药或者说根本无效，现在不知道如何才能针对脑部作有效的治疗，刚刚做了威猛的化疗，身体体质不好，不敢贸然尝试化疗了，您还知道什么靶向药物可以控制肺癌脑转么？或者对于肺癌脑转还有什么办法么?

棕若有情天

脑转,除了放疗就是伽马刀了,其余的根本没办法,尽快吧,我爹就是耽误了,最后放疗都没机会做了,到后期因为肿瘤压迫神经,不能吃,不能喝,不能说话,不能动,还剧痛,简直痛苦到家了

棕若有情天

脑部除了放疗就是伽马刀了,尽快考虑吧,不然就没机会了,我爹就是耽误了,所以都没机会进行放疗了,后期非常痛苦,不能说,不能吃,不能动,还剧痛.尽快吧

jimmy112199

国内能买到脑转药Xcytrin吗？